Guest guest Posted August 9, 2005 Report Share Posted August 9, 2005 In a continued effort to keep the MS community informed of developments surrounding TYSABRI, Biogen Idec and Elan recently announced preliminary findings from the ongoing safety evaluation of TYSABRI. This evaluation was initiated after the voluntary suspension of TYSABRI on February 28, 2005 to better understand any possible link between TYSABRI and progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal neurological disease. To learn more, please click here to read our press release. We expect the final evaluation will be completed at the end of the summer, at which time we will have conversations with regulatory authorities to further define the appropriate path forward. At this time we are not sure if or when TYSABRI will return to the market. Biogen Idec and Elan are committed to patient safety as we continue this important medical and scientific undertaking. We thank you for your patience during this time. We will continue to provide you important new updates and developments. Warm regards, The TYSABRI Team Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.